BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Inc BBIO
News
-
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Gets FDA Acceptance for NDA of Acoramidis
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
The best-performing stock of the year rose nearly 2,000%, while the second best averted disaster to log a tenfold gain in a wild 2023
BridgeBio Seeks FDA Approval of Acoramidis in Transthyretin Amyloid Cardiomyopathy
BridgeBio's stock jumps 3.8% premarket after company announces $250 million PIPE financing led by Qatari sovereign fund
BridgeBio's stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatment
Alibaba, Nio stocks fall, Rivian and Nikola shares rally and other stocks on the move
BridgeBio Pharma shares gain on trial results for dwarfism drug